Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
R125138-10mg | 10mg | In stock | $189.90 | |
R125138-50mg | 50mg | In stock | $325.90 | |
R125138-250mg | 250mg | In stock | $1,467.90 | |
R125138-1g | 1g | In stock | $5,281.90 | |
R125138-5g | 5g | In stock | $23,765.90 | |
R125138-25g | 25g | In stock | $106,944.90 |
Synonyms | B01AF01 | 1429742-50-6 | 2-Thiophenecarboxamide, 5-chloro-N-(((5S)-2-oxo-3-(4-(3-oxo-4-morpholinyl)phenyl)-5-oxazolidinyl)methyl)- | 2w26 | 9NDF7JZ4M3 | Q420262 | Xarelto | MFCD11974010 | N-Smc-carboxylate | L-Glutatione | RIVAROXABAN [ORANGE BOOK] | MLS0 |
---|---|
Specifications & Purity | Moligand™, ≥99% |
Biochemical and Physiological Mechanisms | Rivaroxaban (Xarelto; BAY 59-7939) is a novel, oral, direct Factor Xa (FXa) inhibitor in late-stage development for the prevention and treatment of thromboembolic disorders. Rivaroxaban (Xarelto; BAY 59-7939) inhibits clot-associated,free |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | Coagulation factor X inhibitor |
Product Description | Rivaroxaban is an oral, direct inhibitor of Factor X, being developed for the prevention and treatment of arterial and venous thrombosis with a Ki of 0.4 nM. Rivaroxaban also inhibits prothrombinase activity (IC50 = 2.1 nM). Rivaroxaban also shows a similar affinity to purified human (IC50 = 0.7 nM) and rabbit Factor X (IC50 = 0.8 nM), but a lesser potency against purified rat Factor X (IC50 = 3.4 nM). Endogenous human and rabbit Factor X in plasma is inhibited to a similar extent by Rivaroxaban (IC50 = 21 nM and 21 nM, respectively), while 14-fold higher concentrations are required in rat plasma (IC50 = 290 nM). Rivaroxaban exhibits high permeability and polarized transport across Caco-2 cells as a substrate of the P-gp, but exhibits no inhibitory effect on P-gp-mediated drug transport up to concentrations of 100 μM in vitro. |
ALogP | 2.5 |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
IUPAC Name | 5-chloro-N-[[(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl]methyl]thiophene-2-carboxamide |
---|---|
INCHI | InChI=1S/C19H18ClN3O5S/c20-16-6-5-15(29-16)18(25)21-9-14-10-23(19(26)28-14)13-3-1-12(2-4-13)22-7-8-27-11-17(22)24/h1-6,14H,7-11H2,(H,21,25)/t14-/m0/s1 |
InChi Key | KGFYHTZWPPHNLQ-AWEZNQCLSA-N |
Canonical SMILES | C1COCC(=O)N1C2=CC=C(C=C2)N3CC(OC3=O)CNC(=O)C4=CC=C(S4)Cl |
Isomeric SMILES | C1COCC(=O)N1C2=CC=C(C=C2)N3C[C@@H](OC3=O)CNC(=O)C4=CC=C(S4)Cl |
Alternate CAS | 366789-02-8 |
PubChem CID | 9875401 |
MeSH Entry Terms | 5-chloro-N-(((5S)-2-oxo-3-(4-(3-oxomorpholin-4-yl)phenyl)-1,3-oxazolidin-5-yl)methyl)thiophene-2-carboxamide;BAY 59 7939;BAY 59-7939;BAY 597939;rivaroxaban;xarelto |
Molecular Weight | 435.88 |
PubChem CID | 9875401 |
---|---|
Wikipedia | Rivaroxaban |
ChEMBL Ligand | CHEMBL198362 |
ChEBI | CHEBI:68579 |
CAS Registry No. | 366789-02-8 |
RCSB PDB Ligand | RIV |
PEP | rivaroxaban |
Reactome Reaction | R-HSA-9015122, R-HSA-9015111 |
Reactome Drug | R-ALL-9015055 |
DrugCentral Ligand | 4182 |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
I2226099 | Certificate of Analysis | Jul 10, 2024 | R125138 |
F2214241 | Certificate of Analysis | Mar 20, 2024 | R125138 |
F2214248 | Certificate of Analysis | Mar 20, 2024 | R125138 |
K2125022 | Certificate of Analysis | Sep 11, 2023 | R125138 |
K2125024 | Certificate of Analysis | Sep 11, 2023 | R125138 |
K2125025 | Certificate of Analysis | Sep 11, 2023 | R125138 |
K2125026 | Certificate of Analysis | Sep 11, 2023 | R125138 |
K2125170 | Certificate of Analysis | Sep 11, 2023 | R125138 |
B2021072 | Certificate of Analysis | Sep 05, 2023 | R125138 |
D2121060 | Certificate of Analysis | Feb 09, 2023 | R125138 |
E1522122 | Certificate of Analysis | Nov 11, 2022 | R125138 |
E2424015 | Certificate of Analysis | Jun 23, 2022 | R125138 |
I2226096 | Certificate of Analysis | Jun 23, 2022 | R125138 |
I2226097 | Certificate of Analysis | Jun 23, 2022 | R125138 |
I2226098 | Certificate of Analysis | Jun 23, 2022 | R125138 |
I2226100 | Certificate of Analysis | Jun 23, 2022 | R125138 |
Solubility | DMSO 87 mg/mL Ethanol <1 mg/mL |
---|---|
Specific Rotation[α] | [α]/D -34 to -44, c = 0.3 in DMSO |
Melt Point(°C) | 230 °C |
Pictogram(s) | GHS09 |
---|---|
Hazard Statements | H411:Toxic to aquatic life with long lasting effects |
Precautionary Statements | P273:Avoid release to the environment. P501:Dispose of contents/container to ... P391:Collect spillage. |
1. Ru Li, Xuan Zou, Pan Luan, Xiaokun Liu, Ning Wang, Qian Wang, Huashi Guan, Zhe Xu. (2022) Direct Determination of Enzymes in Dried Blood Spots by High-Performance Liquid Chromatography – Mass Spectrometry (HPLC-MS) for the Screening of Antithrombotic Agents. ANALYTICAL LETTERS, [PMID:] [10.1080/00032719.2022.2053700] |
2. Xu Wang, Dai-Yan Zhang, Shi-Jun Yin, Hui Jiang, Min Lu, Feng-Qing Yang, Yuan-Jia Hu. (2021) Screening of Potential Thrombin and Factor Xa Inhibitors from the Danshen–Chuanxiong Herbal Pair through a Spectrum–Effect Relationship Analysis. MOLECULES, 26 (23): (7293). [PMID:34885877] [10.3390/molecules26237293] |
3. Yang Yi-Yao, Wu Zhao-Yu, Xia Fang-Bo, Zhang Hao, Wang Xu, Gao Jian-Li, Yang Feng-Qing, Wan Jian-Bo. (2020) Characterization of thrombin/factor Xa inhibitors in Rhizoma Chuanxiong through UPLC-MS-based multivariate statistical analysis. Chinese Medicine, 15 (1): (1-14). [PMID:32874198] [10.1186/s13020-020-00376-0] |
4. Yang Yi-Yao, Wu Zhao-Yu, Zhang Hao, Yin Shi-Jun, Xia Fang-Bo, Zhang Qian, Wan Jian-Bo, Gao Jian-Li, Yang Feng-Qing. (2020) LC–MS-based multivariate statistical analysis for the screening of potential thrombin/factor Xa inhibitors from Radix Salvia Miltiorrhiza. Chinese Medicine, 15 (1): (1-13). [PMID:32351617] [10.1186/s13020-020-00320-2] |
5. Zhe Xu, Ruonan Liu, Huashi Guan. (2017) Dual-target inhibitor screening against thrombin and factor Xa simultaneously by mass spectrometry. ANALYTICA CHIMICA ACTA, 990 (1). [PMID:29029731] [10.1016/j.aca.2017.07.063] |
1. Bosch J, Eikelboom JW, Connolly SJ, Bruns NC, Lanius V, Yuan F, Misselwitz F, Chen E, Diaz R, Alings M et al.. (2017) Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial.. Can J Cardiol, 33 (8): (1027-1035). [PMID:28754388] [10.1021/op500134e] |
2. Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, Aboyans V, Alings M, Kakkar AK, Keltai K et al.. (2018) Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.. Lancet, 391 (10117): (219-229). [PMID:29132880] [10.1021/op500134e] |
3. Ru Li, Xuan Zou, Pan Luan, Xiaokun Liu, Ning Wang, Qian Wang, Huashi Guan, Zhe Xu. (2022) Direct Determination of Enzymes in Dried Blood Spots by High-Performance Liquid Chromatography – Mass Spectrometry (HPLC-MS) for the Screening of Antithrombotic Agents. ANALYTICAL LETTERS, [PMID:] [10.1080/00032719.2022.2053700] |
4. Xu Wang, Dai-Yan Zhang, Shi-Jun Yin, Hui Jiang, Min Lu, Feng-Qing Yang, Yuan-Jia Hu. (2021) Screening of Potential Thrombin and Factor Xa Inhibitors from the Danshen–Chuanxiong Herbal Pair through a Spectrum–Effect Relationship Analysis. MOLECULES, 26 (23): (7293). [PMID:34885877] [10.3390/molecules26237293] |
5. Yang Yi-Yao, Wu Zhao-Yu, Xia Fang-Bo, Zhang Hao, Wang Xu, Gao Jian-Li, Yang Feng-Qing, Wan Jian-Bo. (2020) Characterization of thrombin/factor Xa inhibitors in Rhizoma Chuanxiong through UPLC-MS-based multivariate statistical analysis. Chinese Medicine, 15 (1): (1-14). [PMID:32874198] [10.1186/s13020-020-00376-0] |
6. Yang Yi-Yao, Wu Zhao-Yu, Zhang Hao, Yin Shi-Jun, Xia Fang-Bo, Zhang Qian, Wan Jian-Bo, Gao Jian-Li, Yang Feng-Qing. (2020) LC–MS-based multivariate statistical analysis for the screening of potential thrombin/factor Xa inhibitors from Radix Salvia Miltiorrhiza. Chinese Medicine, 15 (1): (1-13). [PMID:32351617] [10.1186/s13020-020-00320-2] |
7. Zhe Xu, Ruonan Liu, Huashi Guan. (2017) Dual-target inhibitor screening against thrombin and factor Xa simultaneously by mass spectrometry. ANALYTICA CHIMICA ACTA, 990 (1). [PMID:29029731] [10.1016/j.aca.2017.07.063] |